<DOC>
	<DOC>NCT00562887</DOC>
	<brief_summary>To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.</brief_summary>
	<brief_title>Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis of Crohn's disease for greater than 4 months confirmed by endoscopy or radiologic evaluation. CDAI score of &gt;= 220 and &lt;= 450 at Week 0. Males and females &gt;= 18 years and &lt; 75 years of age at the Screening visit. Judged to be in generally good health as determined by the Investigator. Current diagnosis of the colitis other than Crohn's disease. Symptomatic known strictures. Surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study. Ostomy or ileoanal pouch. (Subjects with a previous ileorectal anastomosis are not excluded). Short bowel syndrome as determined by the investigator. Infection or risk factors for severe infections. Females who are pregnant or considering becoming pregnant during the study, or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>